Sign In
Buy ADPT
$22.57
-1.61 (-6.66%)
At Close: Jul 31, 2026
Adaptive Biotechnologies: The MRD Separation Creates A Pure-Play Compounder
03:45pm, Friday, 31'st Jul 2026
Adaptive Biotechnologies (ADPT) is transitioning to a pure-play MRD diagnostics company, with the spin-off of Immune Medicine revealing strong underlying profitability. MRD revenue grew 49% year-over-
Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?
10:16am, Friday, 31'st Jul 2026
Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript
12:13am, Thursday, 30'th Jul 2026
Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript
Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say
08:01pm, Wednesday, 29'th Jul 2026
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key m
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates
07:26pm, Wednesday, 29'th Jul 2026
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.17 per share a year ago.
Adaptive Biotechnologies Q2 Earnings Call Highlights
06:05pm, Wednesday, 29'th Jul 2026
Adaptive Biotechnologies NASDAQ: ADPT reported second-quarter results marked by accelerating growth in its minimal residual disease, or MRD, business, improved margins and an increased full-year reven
Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
04:05pm, Wednesday, 29'th Jul 2026
SEATTLE, July 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the gen
Caxton Associates LLP Has $500,000 Stake in Adaptive Biotechnologies Corporation $ADPT
03:26am, Tuesday, 28'th Jul 2026
Caxton Associates LLP trimmed its stake in shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 55.2% in the first quarter, according to the company in its most recent Form 13F filing with
D.A. Davidson & CO. Sells 60,300 Shares of Adaptive Biotechnologies Corporation $ADPT
04:01am, Sunday, 26'th Jul 2026
D.A. Davidson and CO. reduced its holdings in shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 70.1% during the first quarter, according to the company in its most recent disclosure wi
Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:01am, Wednesday, 22'nd Jul 2026
Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adaptive Biotechnologies (ADPT) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Tuesday, 21'st Jul 2026
Adaptive Biotechnologies (ADPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Amova Asset Management Americas Inc. Sells 352,593 Shares of Adaptive Biotechnologies Corporation $ADPT
03:16am, Tuesday, 21'st Jul 2026
Amova Asset Management Americas Inc. lessened its stake in Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 18.1% during the undefined quarter, according to its most recent filing with the Secur
An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run
05:38pm, Sunday, 12'th Jul 2026
Approximately 386,000 shares were liquidated for a total transaction value of $8.5 million on July 2, 2026. This transaction consisted entirely of directly held shares.
Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026
04:05pm, Thursday, 09'th Jul 2026
SEATTLE, July 09, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst
Adaptive Biotechnologies Business Separation May Unlock Greater Value
01:21pm, Wednesday, 17'th Jun 2026
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) on Monday announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses.
